FEBS Letters 583 (2009) 2691–2699
journal homepage: www.FEBSLetters.org
Minireview
Physiological responses to protein aggregates: Fibrinolysis, coagulation
and inflammation (new roles for old factors)
Martijn F.B.G. Gebbink a,b,*, Barend Bouma a, Coen Maas b, Bonno N. Bouma b
a
b
Crossbeta Biosciences B.V., Padualaan 8, 3584 CH Utrecht, The Netherlands
Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
a r t i c l e
i n f o
Article history:
Received 31 March 2009
Revised 10 June 2009
Accepted 10 June 2009
Available online 13 June 2009
Edited by Peter Brzezinski
Keywords:
Amyloid
Crossbeta
Haemostasis
Misfolding
a b s t r a c t
Misfolding is an inherent and potentially problematic propensity of proteins. Misfolded proteins
tend to aggregate and the deposition of aggregated proteins is associated with a variety of highly
debilitating diseases known as amyloidoses. Protein misfolding and aggregation is also increasingly
recognized as the underlying cause of other health problems, including atherosclerosis and immunogenicity of biopharmaceuticals. This raises the question how nature deals with the removal of
obsolete proteins in order to avoid their accumulation and disease. In recent years two proteases,
tPA and factor XII, have been identified that specifically recognize aggregates of misfolded proteins.
We here review these discoveries that have uncovered new roles for the fibrinolytic system and the
contact activation system beyond haemostasis.
Ó 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Causes, appearances and consequences of protein misfolding
To fulfil their specific function proteins typically fold into an
ensemble of closely related three-dimensional structures. This native state is however not stable and all proteins lose eventually
their unique shape (i.e. become ‘‘partially unfolded” or ‘‘partially
denatured”). This is an inherent property of proteins. Of particular
importance in respect to findings reviewed herein is the fact that
proteins unfold and show characteristics of misfolding upon direct
contact with ‘denaturing’ compounds and materials. Such compounds include glass, lipids, metals and sugar polymers. Strikingly,
a number of these ‘denaturing’ materials are also known to activate
the contact system of blood coagulation and/or induce inflammation (see below). As a consequence misfolded proteins can lose
their biological function. More problematic is the fact that misfolded proteins tend to aggregate, which is associated with the
pathology of certain diseases. The propensity of proteins to aggregate varies [1,2] and many environmental conditions can accelerate the aggregation process. Examples include temperature, pH,
oxidative stress, flow stress and glycation as a consequence of
hyperglycemia [3]. As outlined in more detail in other reviews in
this issue one specific type of aggregation is the formation of fibrils,
termed amyloid [4–6]. The structure of the fibrils that are formed
* Corresponding author. Address: Crossbeta Biosciences B.V., Padualaan 8, 3584
CH Utrecht, The Netherlands. Fax: +31 30 253 7131.
E-mail address: [email protected] (M.F.B.G. Gebbink).
by the different proteins is similar [7]. They display a common
structural feature: the amyloid cross-b structure, which is characterized by an organized stacking of b-sheets in the fibrils [8].
Besides the formation of fibrils, protein misfolding can result in a
wide variety of aggregates with various different structural appearances, including intermediates (oligomers) of fibrils and unordered
amorphous aggregates of various sizes. For more detailed information on the formation of aggregates and amyloid fibrils the reader
is referred to excellent reviews [2,9]. It has been demonstrated that
irrespective of the amino acid sequence oligomeric intermediates
which precede amyloid fibril formation do share structural and
functional properties, which are absent in native proteins [10,11].
Due to the nature or size of these aggregates the presence of
cross-b structure in these protein aggregates cannot always be
confirmed by X-ray diffraction, but they show other hallmarks of
amyloid, such as an increased content of b-sheets, affinity for dyes
such thioflavin T and Congo red. Also, amyloid fibrils are detergent
and protease resistant. The term ‘‘amyloid-like” properties is often
used to indicate the presence of characteristics of amyloid in other
aggregates than fibrils. Thus, although aggregates are heterogeneous, they possess common non-native structural and functional
properties. The exact details of these common structural aspects
remain to be elucidated.
For a long time it is known that the formation of amyloid is
associated with many human diseases, known as amyloidoses.
Examples include Alzheimer’s disease and dialysis-related amyloidosis (for more information see [3,9] and in this issue). However,
0014-5793/$36.00 Ó 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.febslet.2009.06.013
2692
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
since protein misfolding and aggregation is such a broad phenomenon it can be anticipated that misfolding and aggregation can
underlie or contribute to other pathologies that are not yet identified as protein misfolding disorders. Such health problems may include atherosclerosis [12], cardiac disease [13] and auto-immune
disorders, such as those associated with the use of biopharmaceuticals [14,15]. Thus, if all proteins can form hazardous species upon
their unfolding, what has nature found to solve this problem? Inside cells non-native proteins are recognized by chaperones and
targeted for refolding or proteolytic degradation. Although quality
control in the extracellular environment has been postulated [16],
it is largely unknown how accumulation of protein aggregation is
prevented outside cells. In recent years, two homologous serine
proteases, tPA and factor XII (FXII), were identified that recognize
misfolded proteins, but not their native precursors [17,18], suggesting that the fibrinolytic system and the contact system play a
role in the detection and clearance of misfolded proteins.
2. Haemostasis and the two routes of inducing coagulation
Haemostasis is the prevention of blood loss as a result of injury
and the coagulation of blood is the protective mechanism.
Coagulation results in the formation of a blood clot (thrombus)
that contains a network of polymerized fibrin with aggregated
platelets. In the classical coagulation model, described in 1964 by
both Macfarlane [19] and by Davie and Ratnoff [20], coagulation
is a proteolytic cascade that can be triggered by two converging
enzymatic pathways, termed the extrinsic pathway and the intrinsic pathway (Fig. 1, panel a). Coagulation via the extrinsic pathway
is initiated by tissue factor (TF), a transmembrane protein exposed
on the injured vessel wall, that binds coagulation factor VII(a). The
complex of activated factor VIIa (FVIIa) and TF activates factor X.
The intrinsic pathway (all factors required for clotting are present
within blood plasma) is activated in vitro when blood comes in
contact with a negatively charged (anionic) surface such as glass
a
b
(Fig. 1, panel b). This results in the activation of the so called contact system which consists of the zymogens factor XII, factor XI,
and prekallikrein (PK) and the non-enzymatic cofactor high molecular weight kininogen (HK). Factor XII binds to the ‘‘surface” and
becomes activated. Activated factor XII leads to the propagation
of the intrinsic pathway by the activation of factor XI with formation of fibrin as its final consequence. Deficiencies of factors in this
cascade (such as factor VIII, factor IX and factor XI) lead to bleeding
disorders. This shows that the lower part of the intrinsic pathway
of coagulation contributes to physiological haemostasis. Paradoxically, deficiencies in the primary contact factors factor XII, PK or
HK, which activate the intrinsic pathway in vitro, are not associated with a bleeding phenotype. This suggests that these three factors do not contribute to this physiological role of the intrinsic
pathway. This contradiction was explained after the identification
of an alternative route of activation of factor XI: thrombin, generated by the extrinsic pathway activates FXI even in the absence
of a negatively charged surface [21–24] (Fig. 1, panel a). The discovery that factor XI is activated in a factor XII-independent manner adds to our understanding of the intrinsic pathway of
coagulation but still leaves factor XII without a physiological
function.
Over the years, next to glass, numerous other materials were
found to induce coagulation of plasma, such as the clay-like materials kaolin [25], metals, polymer sugar, dextran sulfate DXS [26–
29], sulphatide [30] and ellagic acid [31]. Also more physiologically
relevant ‘‘surfaces” have been shown to activate the contact system
and include endothelial cell-associated glycosaminoglycans, certain nucleic acids such as extracellular RNA [32], polyphosphates
[33], and also aggregated amyloid b peptide [34–36]. However,
why the contact system responds to this wide variety of materials
is unclear. Thus, and in addition to its paradoxical role in coagulation, the fact that a clear physiological activator of factor XII remained also unclear, made the real biological role of the contact
system even more mysterious.
c
d
Fig. 1. Classical scheme of the haemostatic systems with the new insights. The formation of a blood clot by coagulation involves the extrinsic and the intrinsic route of
coagulation. (a) The extrinsic route is started upon injury by exposure of tissue factor (TF) on the injured blood vessel to VII. (b) Historically the intrinsic route was found to be
induced (‘contact activated’) when blood contacts an ‘artificial’ (anionic) surface, such as a blood container, which leads to activation of factor XII into aFXIIa. However, a role
of contact activation of the intrinsic system in physiological clotting has not been established and a role for the intrinsic system in the amplification of coagulation was
proposed in which XI is activated by IIa (activated thrombin). (c) The contact system also leads to the formation of an inflammatory response when kallikrein (K) is formed
upon cleavage of prekallikrein (PK) and when high molecular weight kininogen (HK) is cleaved into the vasoactive non-apeptide bradykinin (BK). In this process, a feed-back
loop results in the formation of bFXIIa, which in contrast to aFXIIa is not able to activate FXI into FXIa. (d) The dissolution of a blood clot (fibrinolysis) is mediated by plasmin
(Plm) which degrades fibrin polymers into fibrin degradation products (FDPs). Plasmin (Plm) is formed by the fibrinolytic system, when fibrin-activated tissue-type
plasminogen activator (tPA) cleaves the zymogen plasminogen (Plg). tPA is also activated by misfolded protein aggregates. Moreover fibrin has properties similar to misfolded
proteins (see text). Proteases are depicted in green.
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
3. The kallikrein–kinin system: the formation of bradykinin
Activation of factor XII upon contact with an ‘activating surface’
results not only in the activation of the intrinsic pathway of coagulation but also in the activation of the kallikrein–kinin system by
activation of prekallikrein into kallikrein, leading to an inflammatory response [37,38]. Kallikrein has several functions, but most
notably, it cleaves the potent vasoactive proinflammatory
nona-peptide bradykinin from high molecular weight kininogen
(HK). Hence, the name kallikrein–kinin system for this pathway.
Kallikrein can cleave factor XII(a), resulting in a positive feed-back
loop. A first cleavage causes (surface-bound) factor XII to become
factor XIIa (aFXIIa), the second cleavage causes dissociation of
the light-chain of factor XII, containing the protease domain. Notably, this fragment of factor XII, known as bFXIIa (or factor XIIf), can
activate the kallikrein–kinin system, but not coagulation, in the
absence of a surface [39] (Fig. 1). Thus, two very distinct enzymatic
systems are triggered by active factor XII; one leading to coagulation (in vitro), the other to an inflammatory response.
Kallikrein and bradykinin have a number of roles. First, bradykinin is a potent vasoactive peptide that mediates classical parameters of inflammation, such as redness, fever, swelling, blood
pressure and pain. The peptide acts through two G-protein coupled
receptors, B1 and B2, that are present on a large number of cell
types, but most notably endothelial cells (EC). Activation of the
receptors has a role in recruitment of leukocytes and results also
in the secretion of a number of proinflammatory and chemotactic
cytokines [40]. Secondly, tissue-type plasminogen activator (tPA)
is released by bradykinin stimulated endothelial cells [41–43]. This
indicates an interplay between the kallikrein–kinin system activated by factor XII and the fibrinolytic system activated by tPA
(see below) and a role for bradykinin formation in the activation
of proteases necessary for remodeling of the extracellular matrix,
a process necessary for homeostasis. Thirdly, the contact system
can interact with the complement system: activated factor XII
(bFXIIa) is able to activate the complement system [44–46]. The
complement system is another proteolytic cascade system in blood
involved in host defense reactions, such as protection against bacterial pathogens (for review on fibrinolysis, coagulation and complement see [47]). Although most of the known roles of the
kallikrein–kinin system are unrelated to coagulation, genetic deletion of both the kininogen gene and the bradykinin B2 receptor
gene in mice protects against thrombosis [48,49]. But in contrast,
patient studies show that levels of kallikrein and bradykinin increase after myocardial infarction, which correlates to their survival rates [50]. The kallikrein–kinin system is also shown to be
neuroprotective in rat models of ischemic stroke [51,52]. Also B2
receptor knockout mice display exacerbated post-ischemic brain
injury in a similar model [53]. In conclusion, the activities of the
kallikrein–kinin system are diverse, but its role is likely protective
under physiological conditions in order to preserve or restore
homeostasis, although the system may become detrimental under
pathological circumstances, as discussed in the next paragraph.
2693
Hereditary angioedema (HAE) is a life-threatening affliction
caused by uncontrolled generation of bradykinin, that results in
episodes of swelling in various tissues. The episodes can be triggered by allergy attacks and tissue trauma, but often the cause of
an episode remains unknown. Type III HAE is caused by one of
two known rare mutations in factor XII, that lead to increased factor XII activity [56]. The same pathology, HAE type I or II, is caused
by deficiency or dysfunction of C1-inh, the main inhibitor of the
protease activity of factor XII. The induction of blisters in the skin
of HAE type I and II patients is accompanied by generation of kallikrein in the blister fluid [57].
There are many other diseases, in which the kallikrein–kinin
system has been implicated, independent of its role as inducer of
coagulation [58]. These pathologies include chronic renal failure
[59], proliferative diabetic retinopathy [60], Alzheimer’s disease
(AD) [34,61], arthritis [62–64], vasculitis [65,66], bowel disease
[64], infection and septic shock [67,68], allergy [69,70], schizophrenia [71], preeclampsia [72], recurrent pregnancy loss [73–76] and
cancer [77] and the majority of them have an inflammatory component. Whether activation in all these conditions is protective
or detrimental remains to be established, but an intriguing question that arises is why and how the contact system becomes activated, especially since the presence of contact-activating surfaces
has not been reported in all these conditions. Once again, the identification of physiological activators is required not only to understand the activation of factor XII in vivo but also to explain why
activation of the kallikrein–kinin system is not paralleled by activation of the coagulation system in vivo.
5. The fibrinolytic system
Fibrinolysis is the process that results in the degradation of fibrin polymers during the removal of blood clots. This process contributes to wound healing and haemostasis. Similar to the contact
system, it is a proteolytic mechanism that results in the formation
of one main effector enzyme, plasmin, which cleaves fibrin (Fig. 1,
panel d). Plasmin is formed via activation of its liver-produced
zymogen plasminogen by either tissue-type plasminogen activator
(tPA) or urokinase-type plasminogen activator (uPA). tPA, which is
structurally homologous to factor XII (see below), is released by
activated (endothelial) cells in close vicinity of a blood clot. tPA
binds to the fibrin in the blood clot [78], which results in activation
and enhanced cleavage of plasminogen to yield plasmin. Plasmin in
turn also cleaves tPA, which results in an even more active twochain tPA. In contrast to tPA, uPA does not directly interact with fibrin, but can mediate fibrinolysis when bound to its cellular receptor uPAR. Both plasminogen activators can be inhibited by the
serine-protease inhibitors, such as PAI-1 (plasminogen activator
inhibitor 1), PAI-2 and neuroserpin. The activity of plasmin is
inhibited by plasmin inhibitor, but only when plasmin is not bound
to fibrin.
6. Additional activators and roles for tPA in various processes
other than fibrinolysis
4. Involvement of the contact system in disease
Given the discovery of factor XII as inducer of coagulation
in vitro, there has been special attention for its role in thrombotic
disease. As discussed earlier, and in contrast to its pro-coagulant
activity in vitro, the kallikrein–kinin system has protective properties in myocardial infarction and heart failure [54]. As part of an
all-cause mortality study an inverse correlation was found between the levels of factor XII and the risk of cardiovascular disease
[55]. Similarly, lower factor XII levels were found in patients with
coronary heart disease.
Due to its discovery as initiator of fibrinolysis and its activation
by fibrin polymers, tPA and the fibrinolytic system are associated
with the dissolution of blood clots. However, it has been demonstrated over the years that (1) tPA can be activated by many proteins, (2) plasmin has many substrates other than fibrin and (3)
the ‘fibrinolytic’ system has biological functions independent from
fibrin and separate from its role in blood clot lysis. Examples of
proteins other than fibrin that activate tPA include, extracellular
matrix proteins [79], thrombospondin [80], histidine-proline-rich
glycoprotein [81], maspin [82], actin [83,84], endostatin [85],
2694
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
glycated proteins [86], proteins on the surface of various pathogens
(reviewed in [87]), amyloid-b peptide associated with Alzheimer’s
disease [84,88,89], prion protein of Creutzfeldt-Jakob’s disease
[90], and denatured proteins [91–95]. In addition to polymerized
fibrin in blood clots, also denatured or aggregated forms of its precursor, fibrinogen, can activate tPA [95,96]. Intriguingly, many activators of tPA, including fibrin fragments have been demonstrated
to inhibit angiogenesis and may be applicable to treat cancer
[97,98]. Some potential sites in fibrin have been implicated in the
activation of tPA by fibrin [99], but the exact mechanism of activation by fibrin and by all these other activators remain to be
elucidated.
Plasmin has a broad substrate specificity and degrades other
extracellular matrix proteins such as laminin. In addition, plasmin
activates pro-collagenases, allowing degradation of collagen, and
plasmin cleaves prohormones, for example latent TGFa. Given
their broad specificity it seems unlikely that the role of tPA and
plasmin is limited to the dissolution of fibrin in blood clots. Indeed,
both tPA and plasmin have been demonstrated to play a role in
several processes [100], that include tissue remodeling and most
notably, neuronal cell migration and neuronal function, such as
long term potentiation [101].
Studies indicate that tPA modulates the deposition of amyloid-b
peptide that is associated with Alzheimer’s disease [84,102–104].
Plasmin degrades amyloid-b aggregates in vitro [84,104] and amyloid-b injected into the brain is not removed in tPA-deficient mice
[103]. Based on these findings the effects of a PAI-1 inhibitor was
studied in a mouse model of Alzheimer’s disease [102]. This compound, which sustains plasmin activity, enhanced amyloid-b clearance. Thus activation of fibrinolysis may be a novel disease
modifying treatment for amyloidosis. However, tPA can also be
detrimental. In animal models it has been shown that tPA is an
essential element in the induction of excitotoxic injury [105]. As
with the contact system, the fibrinolytic system is implicated in
a large number of pathologies, including amyloidosis, cancer, infections, atherosclerosis and auto-immune diseases. Another intriguing overlap between the activation of the contact system by
‘surfaces’ and the activation of the fibrinolytic system is that plasminogen plays a central role in the inflammatory response to biomaterials [106].
Taken together, this leads to the central questions: (1) what is
the common denominator among all these different activators of
factor XII and tPA and (2) how do these factors bind to their various
activators. Recent publications have gained insight into these two
questions.
7. Misfolded proteins comprise similar features that activate
tPA and factor XII
As described above and in detail elsewhere in this issue and
other reviews proteins can aggregate in multiple ways, resulting
in aggregates with heterogeneous appearances. Also, not all unfolded proteins will aggregate, be toxic or have an amyloid-like
structure. Aggregates can be amorphous, form oligomers or fibrils.
Within these varieties, common structural and functional properties have been found, including the propensity to induce cellular
toxicity [10,11]. The details of the structural commonalities in oligomers and amorphous aggregates remain to be elucidated, as well
as the exact mechanism(s) responsible for the cellular toxicity. The
current evidence implicates so-called soluble oligomers as the
most toxic species (see other reviews in this issue). Common structural characteristics of misfolding and subsequent amyloid fibril
formation include the increase in b-sheet content and folding into
the cross-b structure. Such features are directly measured using
circular dichroism (for b-sheet content) and X-ray fibre diffraction
(cross-b structure). Alternatively certain dyes, most notably thioflavin T (ThT), can be used. Its binding induces fluorescence and
is indicative for structural changes reminiscent to amyloid crossb structure. The exact mode of binding of thioflavin T remains however to be established, although recent publications indicate that
thioflavin T binds in cavities of the amyloid fibrils [107,108]. Native
proteins do generally not comprise properties common to amyloid
fibrils or their precursors, including affinity for thioflavin T and
presence of cross-b structure.
Based on the fact that tPA was activated by numerous proteins,
including denatured proteins and amyloid-b (see above) we
hypothesized that tPA is activated by common features to misfolded proteins and demonstrated that tPA is indeed a cross-b
structure receptor [18]. We demonstrated that activation of tPA
correlated with the presence of cross-b structure and is independent of the amino acid sequence of the underlying protein
(Fig. 2a). Moreover, the binding of tPA to misfolded proteins comprising cross-b structure could be inhibited with Congo red (Bouma, unpublished). Subsequently we established that the
homologous protease, factor XII, is activated by misfolded proteins
as well and that this leads to kallikrein formation but not to activation of factor XI into XIa [17] (Fig. 2b–d). Activation of factor XII
resulting in kallikrein formation was only observed with misfolded
protein aggregates but not with native, monomeric species nor
with amyloid fibrils. We also demonstrated activation of both the
contact system and the fibrinolytic system in vivo in patients with
systemic amyloidosis [17,109]. In line with the results in vitro,
activation of the kallikrein system was seen in patients with amyloidosis, but no activation of factor XI was notable [17]. These findings uncovered a possible role for tPA and factor XII in modulating
protein misfolding and protein misfolding diseases.
8. Surface-induced conformational changes reminiscent of
misfolding underly the mechanism of activation of the contact
system
In our efforts to elucidate the physiological mechanism of activation of factor XII we examined the role of protein misfolding in
classical activation of factor XII by surfaces [17]. For a long time
it is known that the contact system is activated by ‘surfaces’ and
that this results in activation of factor XI and prekallikrein. It is also
well known that proteins adsorb to surfaces, such as glass, polymers and also phospholipids. The adsorption of proteins depends
on the molecular weight and with time a low molecular weight
protein is displaced by higher molecular weight proteins. This effect is known as the Vroman effect and was established with blood
plasma [110]. Many publications have demonstrated that protein
adsorption can result in structural changes and denaturation of
these adsorbed proteins [111,112]. One example includes fibrinogen, the precursor protein of fibrin in blood clots, adsorbed to glass
[113]. Recent studies have now also directly demonstrated protein
adsorption to certain materials, including phospholipids [114,115]
and surfaces, like mica [116], with the formation of the structural
features common to misfolded proteins and reminiscent of amyloid. In our recent work on the activation of the contact system
we showed that the activation of prekallikrein by factor XII could
not be induced by a ‘surface’ alone, but was completely dependent
on the presence of sufficient amounts of protein [17] (Fig. 2e). We
also demonstrated that the surfaces that induce factor XII activation through a cofactor protein also induced conformational
changes in these cofactor proteins that likely underly the activation of factor XII (Fig. 2f). Whereas activation of the kallikrein system required addition of proteins (to be denatured by the surface)
activation of factor XI was seen in the absence of proteins (Fig. 2d).
Hence activation of factor XI can be triggered by direct contact of
2695
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
0.7
Buffer
Plasmin activity
(OD405nm)
0.6
30 µg/mL nOVA
0.5
5 µg/mL dOVA
0.4
10 µg/ml dOVA
0.3
15 µg/mL dOVA
0.2
20 µg/mL dOVA
0.1
25 µg/mL dOVA
0.0
0
25
50
75
100
30 µg/mL dOVA
125
Time (min)
Kallikrein activity
(OD405nm)
b
0.5
Buffer
100 µg/mL dOVA
50 µg/mL dOVA
25 µg/mL dOVA
12.5 µg/mL dOVA
0.4
0.3
0.2
0.1
c
0.5
Kallikrein activity
(OD405nm)
a
0.0
Buffer
100 µg/mL nOVA
50 µg/mL nOVA
25 µg/mL nOVA
12.5 µg/mL nOVA
0.4
0.3
0.2
0.1
0.0
25
50
75
25
100 125 150 175 200
50
Time (min)
Factor XIa activity
(OD405nm)
d
75
100 125 150 175 200
Time (min)
0.7
Buffer
DXS500k
BSA-AGE 10 µg/mL
BSA-AGE 5 µg/mL
BSA-AGE 2.5 µg/mL
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
50
100
150
200
Time (min)
0.6
1 mg/mL BSA
0.5
150 µg/mL Kaolin
BSA + Kaolin
Buffer
0.4
0.3
0.2
0.1
f
CD (mDeg)
Kallikrein activity
(OD405nm)
e
0
-5
BSA
BSA + Kaolin
BSA + EA
BSA + DXS
-10
0.0
-0.1
0
25
50
75
100
Time (min)
-15
265
275
285
295
305
Wavelength (nm)
Fig. 2. Activation of the fibrinolytic system (tPA) and the kallikrein–kinin system (factor XII) by misfolded proteins. (a) Stimulation of tPA-mediated plasminogen activation
by two forms ovalbumin (OVA), one with (heat denatured OVA, dOVA) and one without amyloid properties (native OVA, nOVA). (b) Factor XII mediated kallikrein generation
induced by misfolded OVA (inset: electronmicroscopic picture of dOVA protein aggregates activating factor XII). (c) Freshly dissolved OVA does not activate factor XII. (d)
Factor XII-dependent activation of factor XI is not stimulated by misfolded proteins (BSA-AGE). (e) Factor XII-dependent kallikrein generation by a surface (shown is kaolin) is
mediated by cofactor proteins. (f) Circular dichroism measurements (near UV spectra) indicate changes in tertiary structure of BSA in the presence of surfaces, kaolin, ellagic
acid (EA) and dextrane sulfate (DXS) that are known activators of factor XII. For additional data and detailed information see [17]. (b–f) are reproduced with permission from
The Journal of Clinical Investigation [17]. BSA-AGE: Bovine serum albumin misfolded through glycation, producing advanced glycation end-products comprising amyloid
properties [135].
factor XII to the surface. The mechanism is still unknown, but may
involve conformational changes and autoactivation of factor XII
upon binding to the surface. Such changes have been observed
[117]. A thorough analysis of the literature revealed that in the past
factor XII activation studies were always performed in the presence of protein in the assay buffer, which explains previously observed kallikrein activation. Recently it was concluded that the
paradigm that negatively charged surfaces activate the contact system required substantial revision as also positively charged mate-
rials can activate factor XII and that the protein composition of the
fluid plays an important role [118]. Our work has now demonstrated that the real trigger for activation of factor XII for formation
of kallikrein is the change in protein conformation, i.e. induction of
unfolding and misfolding, due to contact of a native protein with a
non-compatible surface. In this view, the activation of prekallikrein
by factor XII observed in all previous studies should be reconsidered. In these studies the activator of factor XII may in fact be a
protein unfolding (misfolding) inducing agent. Taken together,
2696
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
our work has changed the view on the activation of factor XII and
revealed insight into the physiological role of the contact system
(see below). These findings are of particular importance for the
safety of biomaterials, such as stents, and for the manufacturing,
packaging, and storage of biopharmaceuticals [14,15,119]. Hence
tPA and factor XII can be applied as sensitive measurement methods of biomaterial hemocompatibility and the quality of biopharmaceuticals [15,120]. This may help to decrease the adverse
inflammatory effects of biomaterials, such as hemodialysis systems
or stents, and the immunogenicity of biopharmaceuticals.
9. The fibronectin type I domain (‘finger domain’) – a motif that
binds misfolded proteins
How do factor XII and tPA recognize their activators, i.e. misfolded proteins. These proteases are quite homologous and comprise several distinct motifs (Fig. 3). Using deletion mutants and
recombinantly produced domains we recently mapped the binding
site to the fibronectin type I (or ‘finger’) domain [121]. We also
found that similar domains in yet another homologous protein,
hepatocyte growth factor activator (HGFA) and in the extracellular
matrix protein fibronectin bind protein aggregates. We demonstrated that isolated fibronectin type I domains can inhibit platelet
aggregation induced by misfolded protein aggregates, which may
offer new therapeutic strategies to treat diseases associated with
protein misfolding. The same domains were previously shown to
mediate the interaction of tPA with fibrin [78,122] and fibronectin
with fibrin [123]. This suggests that the interaction of tPA with
misfolded proteins and fibrin may result from common structural
features. Hence, does fibrin has amyloid-like properties?
10. What about misfolding properties in fibrin?
Some specific amino acid sequences in fibrin have been identified to induce tPA activation [124]. However, the evidence has been
gathered with the use of synthetic peptides. We showed, at least
for one peptide (amino acid 148–160 of the alpha-chain of fibrin
(ogen), that, while the crystal structure predicts the formation of
a-helix, these peptides form cross-b structure in vitro [18]. At present it is widely accepted that the structural changes leading to the
exposure of sites thought to bind t-PA and/or plasminogen remain
to be demonstrated [125]. We studied structural properties of fibrin and found that fibrin has structural properties reminiscent
of amyloid (Bouma, manuscript submitted). Thrombin-induced
polymerized fibrin binds the amyloid dyes, Congo red and thioflavin T. Fibrin also binds serum amyloid P (SAP), a protein used to
diagnose amyloidosis also in vivo [126]. Finally we demonstrated
the presence of cross-b structure using X-ray fibre diffraction analysis. Our results fit with early data on the structural changes that
are associated with the conversion of fibrinogen into fibrin that
showed that fibrin formation is accompanied by a general increase
in b-sheet formation of hydrogen bonds between adjacent fibrin
molecules [127]. This type of interaction within the fibrin meshwork is similar to that underlying the cross-b structure in amyloid,
suggesting that these cross-b structures are formed during fibrin
polymerization. Hence, this common structural element, which
can be formed by a myriad of proteins including fibrin, triggers
fibrinolysis, contributing to the removal of obsolete proteins, such
as fibrin in blood clots, and potentially also all other proteins. Just
recently, it was shown that fibrin also activates factor XII [128],
supporting the idea that a common structural element is present
in fibrin and protein aggregates to activate both tPA and factor XII.
11. The Crossbeta pathway: new roles for two old factors
Together, new roles have been identified for two old factors:
factor XII and tPA. We have shown that both the contact system
and the fibrinolytic system react to misfolded proteins of various
origin. Activation of factor XII by misfolded proteins leads to kallikrein and BK formation but not to factor XIa generation. This implies that in this situation the intrinsic pathway of coagulation is
not triggered but that instead a fast vasoactive and proinflammatory response is the result. The fibrinolytic system is also activated
because BK induces the release of tPA from endothelial cells while
kallikrein activates both urokinase-type plasminogen activator and
plasminogen. Earlier, we reported that tPA-dependent plasmin for-
Fig. 3. Schematic representation of the structure of factor XII, tPA, HGFA and fibronectin. Domain architecture of tPA, factor XII, hepatocyte growth factor activator (HGFA)
and fibronectin. F, fibronectin type I (‘finger’) domain; E, EGF-like domain; II, fibronectin type II domain; III, fibronectin type III domain; Pr, proline-rich region; K, Kringle; P,
protease domain.
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
mation is stimulated by misfolded proteins. Plasmin not only degrades fibrin clots but also plays a role in inflammation and wound
repair. Evidence for the generation of kallikrein but not FXIa and
activation of the fibrinolytic system was obtained in patients with
systemic amyloidosis. Activation of factor XII resulting in kallikrein
formation was only observed with misfolded protein aggregates
but not with native, monomeric species or amyloid fibrils. The protein aggregates resemble prefibrillar, oligomeric species that are
held responsible for the toxicity seen in protein misfolding disease.
We therefore propose that the contact system and the fibrinolytic
system contribute under normal conditions to the detection and
removal of otherwise potential harmful protein aggregates, before
they become protease resistant amyloid fibrils. As mentioned
above activation of the contact system was observed in a wide
variety of diseases i.e. diabetic retinopathy, lactic acidosis and
inflammatory bowel disease. It is tempting to speculate that in
these conditions for instance changes in pH have led to the formation of misfolded proteins and as a consequence activation of factor
XII. Since misfolded proteins can be formed under a variety of conditions (e.g. pH, temperature, oxidative stress, flow stress, glycation) and by a large number of ‘‘denaturing” compounds and
materials (e.g. glass, lipids, endothelial associated glycosaminoglycans, RNA) it is anticipated that protein aggregation is much more
wide spread than currently known. For example, protein aggregation may underly pathological conditions with at present unknown
etiology in which factor XII activation has been implicated, i.e.
auto-immune disease such as those associated with the use of biopharmaceuticals or the anaphylactic reactions observed with certain preparations of heparin that were contaminated with
oversulfated chondroitin sulfate [129,130].
Unfolding of proteins is a fact of nature. We propose that with
the identification of tPA and factor XII we have uncovered an ancient pathway for the clearance of unfolded proteins that facilitates
protein homeostasis and prevents against protein misfolding diseases. This fits well with the suggested protective role for factor
XII [55]. The complement system and certain scavenger receptors,
like the receptor for advanced glycation end-products RAGE
[131,132], CD36 [133] and LRP [134] that were also shown to bind
certain amyloids are likely part of this pathway. We have termed
this clearance mechanism for obsolete proteins the ‘cross-b pathway’ [135] (Fig. 4). Modulating the cross-b pathway is an attractive
strategy for the treatment of protein misfolding diseases, which are
mostly highly debilitating and currently untreatable.
Fig. 4. Scheme of Crossbeta pathway with the new role for the contact and
fibrinolytic system. FX, factor XII; BK, bradykinin; Plm, plasmin.
2697
Conflict of interest
The authors are employees and/or hold shares in Crossbeta
Biosciences, a spin-off company of the Utrecht University and
University Medical Center Utrecht.
Acknowledgements
We thank Johan Renes and Cornelis Kluft for their advice and
support. We thank all our other colleagues of Crossbeta Biosciences
and the University Medical Center Utrecht and our collaborators,
who have all contributed to our studies and publications, for their
excellent work and many helpful discussions in the course of our
studies.
References
[1] Tartaglia, G.G. and Vendruscolo, M. (2008) The Zyggregator method for
predicting protein aggregation propensities. Chem. Soc. Rev. 37, 1395–1401.
[2] Rousseau, F., Schymkowitz, J. and Serrano, L. (2006) Protein aggregation and
amyloidosis: confusion of the kinds? Curr. Opin. Struct. Biol. 16, 118–126.
[3] Herczenik, E. and Gebbink, M.F. (2008) Molecular and cellular aspects of
protein misfolding and disease. FASEB J. 22, 2115–2133.
[4] Chiti, F. (2009) FEBS Lett., this issue.
[5] Luheshi, L.M. and Dobson, C.M. (2009) Bridging the gap: from protein
misfolding to protein misfolding diseases. FEBS Lett., doi:10.1016/
j.febslet.2009.06.030.
[6] Langkilde, A.E. and Vestergaard, B. (2009) Methods for structural
characterization of prefibrillar intermediates and amyloid fibrils. FEBS Lett.,
doi:10.1016/j.febslet.2009.05.040.
[7] Rochet, J.C. and Lansbury Jr., P.T. (2000) Amyloid fibrillogenesis: themes and
variations. Curr. Opin. Struct. Biol. 10, 60–68.
[8] Nelson, R. and Eisenberg, D. (2006) Structural models of amyloid-like fibrils.
Adv. Protein Chem. 73, 235–282.
[9] Chiti, F. and Dobson, C.M. (2006) Protein misfolding, functional amyloid, and
human disease. Annu. Rev. Biochem. 75, 333–366.
[10] Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei,
N., Ramponi, G., Dobson, C.M. and Stefani, M. (2002) Inherent toxicity of
aggregates implies a common mechanism for protein misfolding diseases.
Nature 416, 507–511.
[11] Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W.
and Glabe, C.G. (2003) Common structure of soluble amyloid oligomers
implies common mechanism of pathogenesis. Science 300, 486–489.
[12] Howlett, G.J. and Moore, K.J. (2006) Untangling the role of amyloid in
atherosclerosis. Curr. Opin. Lipidol. 17, 541–547.
[13] Pattison, J.S. and Robbins, J. (2008) Protein misfolding and cardiac disease:
establishing cause and effect. Autophagy 4, 821–823.
[14] Frokjaer, S. and Otzen, D.E. (2005) Protein drug stability: a formulation
challenge. Nat. Rev. Drug Discov. 4, 298–306.
[15] Maas, C., Hermeling, S., Bouma, B., Jiskoot, W. and Gebbink, M.F. (2007) A role
for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol.
Chem. 282, 2229–2236.
[16] Yerbury, J.J., Stewart, E.M., Wyatt, A.R. and Wilson, M.R. (2005) Quality
control of protein folding in extracellular space. EMBO Rep. 6, 1131–1136.
[17] Maas, C., Govers-Riemslag, J.W., Bouma, B., Schiks, B., Hazenberg, B.P.,
Lokhorst, H.M., Hammarstrom, P., ten, C.H., de Groot, P.G., Bouma, B.N. and
Gebbink, M.F. (2008) Misfolded proteins activate factor XII in humans,
leading to kallikrein formation without initiating coagulation. J. Clin. Invest.
118, 3208–3218.
[18] Kranenburg, O., Bouma, B., Kroon-Batenburg, L.M., Reijerkerk, A., Wu, Y.P.,
Voest, E.E. and Gebbink, M.F. (2002) Tissue-type plasminogen activator is a
multiligand cross-beta structure receptor. Curr. Biol. 12, 1833–1839.
[19] Macfarlane, R.G. (1964) An enzyme cascade in the blood clotting mechanism,
and its function as a biochemical amplifier. Nature 202, 498–499.
[20] Davie, E.W. and Ratnoff, O.D. (1964) Waterfall sequence for intrinsic blood
clotting. Science 145, 1310–1312.
[21] Bouma, B.N., von dem Borne, P.A. and Meijers, J.C. (1998) Factor XI and
protection of the fibrin clot against lysis—a role for the intrinsic pathway of
coagulation in fibrinolysis. Thromb. Haemost. 80, 24–27.
[22] von dem Borne, P.A., Meijers, J.C. and Bouma, B.N. (1995) Feedback
activation of factor XI by thrombin in plasma results in additional
formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86,
3035–3042.
[23] Gailani, D. and Broze Jr., G.J. (1991) Factor XI activation in a revised model of
blood coagulation. Science 253, 909–912.
[24] Naito, K. and Fujikawa, K. (1991) Activation of human blood coagulation
factor XI independent of factor XII. Factor XI is activated by thrombin and
factor XIa in the presence of negatively charged surfaces. J. Biol. Chem. 266,
7353–7358.
[25] Margolis, J. (1957) Initiation of blood coagulation by glass and related
surfaces. J. Physiol. 137, 95–109.
2698
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
[26] Silverberg, M. and Diehl, S.V. (1987) The autoactivation of factor XII
(Hageman factor) induced by low-Mr heparin and dextran sulphate. The
effect of the Mr of the activating polyanion. Biochem. J. 248, 715–720.
[27] Silverberg, M. (1989) Hageman factor activation by polysaccharides: effect of
molecular weight. Adv. Exp. Med. Biol. 247A, 453–460.
[28] Kluft, C. (1978) Determination of prekallikrein in human plasma: optimal
conditions for activating prekallikrein. J. Lab Clin. Med. 91, 83–95.
[29] van der Graaf, F., Keus, F.J., Vlooswijk, R.A. and Bouma, B.N. (1982) The
contact activation mechanism in human plasma: activation induced by
dextran sulfate. Blood 59, 1225–1233.
[30] Fujikawa, K., Heimark, R.L., Kurachi, K. and Davie, E.W. (1980) Activation of
bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 19,
1322–1330.
[31] Bock, P.E., Srinivasan, K.R. and Shore, J.D. (1981) Activation of intrinsic blood
coagulation by ellagic acid: insoluble ellagic acid–metal ion complexes are
the activating species. Biochemistry 20, 7258–7266.
[32] Kannemeier, C., Shibamiya, A., Nakazawa, F., Trusheim, H., Ruppert, C.,
Markart, P., Song, Y., Tzima, E., Kennerknecht, E., Niepmann, M., von Bruehl,
M.L., Sedding, D., Massberg, S., Gunther, A., Engelmann, B. and Preissner, K.T.
(2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood
coagulation. Proc. Natl. Acad. Sci. USA 104, 6388–6393.
[33] Smith, S.A. and Morrissey, J.H. (2008) Polyphosphate as a general
procoagulant agent. J. Thromb. Haemost. 6, 1750–1756.
[34] Bergamaschini, L., Donarini, C., Gobbo, G., Parnetti, L. and Gallai, V. (2001)
Activation of complement and contact system in Alzheimer’s disease. Mech.
Ageing Dev. 122, 1971–1983.
[35] Bergamaschini, L., Donarini, C., Foddi, C., Gobbo, G., Parnetti, L. and Agostoni,
A. (2001) The region 1–11 of Alzheimer amyloid-beta is critical for activation
of contact-kinin system. Neurobiol. Aging 22, 63–69.
[36] Joseph, K., Shibayama, Y., Nakazawa, Y., Peerschke, E.I., Ghebrehiwet, B. and
Kaplan, A.P. (1999) Interaction of factor XII and high molecular weight
kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and
with aggregated Abeta protein of Alzheimer’s disease. Immunopharmacology
43, 203–210.
[37] Burch, R.M., Connor, J.R. and Tiffany, C.W. (1989) The kallikrein–kininogen–
kinin system in chronic inflammation. Agents Actions 27, 258–260.
[38] Zimmerli, W., Huber, I., Bouma, B.N. and Lammle, B. (1989) Purified human
plasma kallikrein does not stimulate but primes neutrophils for superoxide
production. Thromb. Haemost. 62, 1121–1125.
[39] Revak, S.D., Cochrane, C.G., Bouma, B.N. and Griffin, J.H. (1978) Surface and
fluid phase activities of two forms of activated Hageman factor produced
during contact activation of plasma. J. Exp. Med. 147, 719–729.
[40] Koyama, S., Sato, E., Nomura, H., Kubo, K., Miura, M., Yamashita, T., Nagai, S.
and Izumi, T. (1998) Bradykinin stimulates type II alveolar cells to release
neutrophil and monocyte chemotactic activity and inflammatory cytokines.
Am. J. Pathol. 153, 1885–1893.
[41] Brown, N.J., Nadeau, J.H. and Vaughan, D.E. (1997) Selective stimulation of
tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin.
Thromb. Haemost. 77, 522–525.
[42] Brown, N.J., Gainer, J.V., Stein, C.M. and Vaughan, D.E. (1999) Bradykinin
stimulates tissue plasminogen activator release in human vasculature.
Hypertension 33, 1431–1435.
[43] Brown, N.J., Gainer, J.V., Murphey, L.J. and Vaughan, D.E. (2000) Bradykinin
stimulates tissue plasminogen activator release from human forearm
vasculature through B(2) receptor-dependent, NO synthase-independent,
and cyclooxygenase-independent pathway. Circulation 102, 2190–2196.
[44] DiScipio, R.G. (1982) The activation of the alternative pathway C3 convertase
by human plasma kallikrein. Immunology 45, 587–595.
[45] Ghebrehiwet, B., Silverberg, M. and Kaplan, A.P. (1981) Activation of the
classical pathway of complement by Hageman factor fragment. J. Exp. Med.
153, 665–676.
[46] Wiggins, R.C., Giclas, P.C. and Henson, P.M. (1981) Chemotactic activity
generated from the fifth component of complement by plasma kallikrein of
the rabbit. J. Exp. Med. 153, 1391–1404.
[47] Caliezi, C., Wuillemin, W.A., Zeerleder, S., Redondo, M., Eisele, B. and Hack,
C.E. (2000) C1-Esterase inhibitor: an anti-inflammatory agent and its
potential use in the treatment of diseases other than hereditary
angioedema. Pharmacol. Rev. 52, 91–112.
[48] Merkulov, S., Zhang, W.M., Komar, A.A., Schmaier, A.H., Barnes, E., Zhou, Y.,
Lu, X., Iwaki, T., Castellino, F.J., Luo, G. and McCrae, K.R. (2008) Deletion of
murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and
delays thrombosis. Blood 111, 1274–1281.
[49] Shariat-Madar, Z., Mahdi, F., Warnock, M., Homeister, J.W., Srikanth, S.,
Krijanovski, Y., Murphey, L.J., Jaffa, A.A. and Schmaier, A.H. (2006) Bradykinin
B2 receptor knockout mice are protected from thrombosis by increased nitric
oxide and prostacyclin. Blood 108, 192–199.
[50] Hashimoto, K., Hamamoto, H., Honda, Y., Hirose, M., Furukawa, S. and Kimura,
E. (1978) Changes in components of kinin system and hemodynamics in
acute myocardial infarction. Am. Heart J. 95, 619–626.
[51] Xia, C.F., Yin, H., Borlongan, C.V., Chao, L. and Chao, J. (2004) Kallikrein gene
transfer protects against ischemic stroke by promoting glial cell migration
and inhibiting apoptosis. Hypertension 43, 452–459.
[52] Xia, C.F., Yin, H., Yao, Y.Y., Borlongan, C.V., Chao, L. and Chao, J. (2006)
Kallikrein protects against ischemic stroke by inhibiting apoptosis and
inflammation and promoting angiogenesis and neurogenesis. Hum. Gene
Ther. 17, 206–219.
[53] Xia, C.F., Smith Jr., R.S., Shen, B., Yang, Z.R., Borlongan, C.V., Chao, L. and Chao,
J. (2006) Postischemic brain injury is exacerbated in mice lacking the kinin B2
receptor. Hypertension 47, 752–761.
[54] Doggen, C.J., Rosendaal, F.R. and Meijers, J.C. (2006) Levels of intrinsic
coagulation factors and the risk of myocardial infarction among men:
opposite and synergistic effects of factors XI and XII. Blood 108, 4045–4051.
[55] Endler, G., Marsik, C., Jilma, B., Schickbauer, T., Quehenberger, P. and
Mannhalter, C. (2007) Evidence of a U-shaped association between factor
XII activity and overall survival. J. Thromb. Haemost. 5, 1143–1148.
[56] Cichon, S., Martin, L., Hennies, H.C., Muller, F., Van, D.K., Karpushova, A.,
Stevens, W., Colombo, R., Renne, T., Drouet, C., Bork, K. and Nothen, M.M.
(2006) Increased activity of coagulation factor XII (Hageman factor) causes
hereditary angioedema type III. Am. J. Hum. Genet. 79, 1098–1104.
[57] Curd, J.G., Prograis Jr., L.J. and Cochrane, C.G. (1980) Detection of active
kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp.
Med. 152, 742–747.
[58] Costa-Neto, C.M., Llenburg-Pilla, P., Heinrich, T.A., Parreiras-e-Silva, L.T.,
Pereira, M.G., Reis, R.I. and Souza, P.P. (2008) Participation of kallikrein–kinin
system in different pathologies. Int. Immunopharmacol. 8, 135–142.
[59] Jozwiak, L., Drop, A., Buraczynska, K., Ksiazek, P., Mierzicki, P. and
Buraczynska, M. (2004) Association of the human bradykinin B2 receptor
gene with chronic renal failure. Mol. Diagn. 8, 157–161.
B.B., Chen, X., Timothy, N., Aiello, L.P. and Feener, E.P. (2008)
Gao,
[60]
Characterization of the vitreous proteome in diabetes without diabetic
retinopathy and diabetes with proliferative diabetic retinopathy. J. Proteome
Res. 7, 2516–2525.
[61] Bergamaschini, L., Parnetti, L., Pareyson, D., Canziani, S., Cugno, M. and
Agostoni, A. (1998) Activation of the contact system in cerebrospinal fluid of
patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 102–108.
[62] McLaren, M., Alkaabi, J., Connacher, M., Belch, J.J. and Valenete, E. (2002)
Activated factor XII in rheumatoid arthritis. Rheumatol. Int. 22, 182–184.
[63] Espinola, R.G., Uknis, A., Sainz, I.M., Isordia-Salas, I., Pixley, R., DeLa, C.R., Long,
W., Agelan, A., Gaughan, J., Adam, A. and Colman, R.W. (2004) A monoclonal
antibody to high-molecular weight kininogen is therapeutic in a rodent
model of reactive arthritis. Am. J. Pathol. 165, 969–976.
[64] Colman, R.W. (1999) Plasma and tissue kallikrein in arthritis and
inflammatory bowel disease. Immunopharmacology 43, 103–108.
[65] Becker, C.G., Dubin, T. and Glenn, F. (1980) Induction of acute cholecystitis by
activation of factor XII. J. Exp. Med. 151, 81–90.
[66] Kahn, R., Herwald, H., Muller-Esterl, W., Schmitt, R., Sjogren, A.C., Truedsson,
L. and Karpman, D. (2002) Contact-system activation in children with
vasculitis. Lancet 360, 535–541.
[67] Frick, I.M., Bjorck, L. and Herwald, H. (2007) The dual role of the contact
system in bacterial infectious disease. Thromb. Haemost. 98, 497–502.
[68] Hack, C.E. and Colman, R.W. (1999) The role of the contact system in the
pathogenesis of septic shock. Sepsis 3, 111–118.
[69] Dotsenko, V.L., Nenasheva, N.M., Neshkova, E.A., Morozova, N.A. and Yarovaya,
G.A. (1989) Mechanism of activation of the kallikrein–kinin system in plasma
of patients with atopic allergic diseases. Adv. Exp. Med. Biol. 247B, 515–521.
[70] Atkins, P.C., Miragliotta, G., Talbot, S.F., Zweiman, B. and Kaplan, A.P. (1987)
Activation of plasma Hageman factor and kallikrein in ongoing allergic
reactions in the skin. J. Immunol. 139, 2744–2748.
[71] Shcherbakova, I., Neshkova, E., Dotsenko, V., Platonova, T., Shcherbakova, E.
and Yarovaya, G. (1999) The possible role of plasma kallikrein–kinin system
and
leukocyte
elastase
in
pathogenesis
of
schizophrenia.
Immunopharmacology 43, 273–279.
[72] Vaziri, N.D., Toohey, J., Powers, D., Keegan, K., Gupta, A., Alikhani, S., Mashood,
M. and Barbari, A. (1986) Activation of intrinsic coagulation pathway in preeclampsia. Am. J. Med. 80, 103–107.
[73] Matsubayashi, H., Sugi, T., Suzuki, T., Uchida, N., Atsumi, H., Izumi, S. and
Mikami, M. (2008) Decreased factor XII activity is associated with recurrent
IVF-ET failure. Am. J. Reprod. Immunol. 59, 316–322.
[74] Ogasawara, M.S., Aoki, K., Katano, K., Ozaki, Y. and Suzumori, K. (2001) Factor
XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of
recurrent miscarriage. Fertil. Steril. 75, 916–919.
[75] Ogasawara, M.S., Iinuma, Y., Aoki, K., Katano, K., Ozaki, Y. and Suzumori, K.
(2001) Low-dose aspirin is effective for treatment of recurrent miscarriage in
patients with decreased coagulation factor XII. Fertil. Steril. 76, 203–204.
[76] Pauer, H.U., Burfeind, P., Kostering, H., Emons, G. and Hinney, B. (2003) Factor
XII deficiency is strongly associated with primary recurrent abortions. Fertil.
Steril. 80, 590–594.
[77] Maeda, H., Wu, J., Okamoto, T., Maruo, K. and Akaike, T. (1999) Kallikrein–
kinin in infection and cancer. Immunopharmacology 43, 115–128.
[78] van Zonneveld, A.J., Veerman, H. and Pannekoek, H. (1986) On the interaction
of the finger and the kringle-2 domain of tissue-type plasminogen activator
with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic
acid. J. Biol. Chem. 261, 14214–14218.
[79] Stack, S., Gonzalez-Gronow, M. and Pizzo, S.V. (1990) Regulation of
plasminogen activation by components of the extracellular matrix.
Biochemistry 29, 4966–4970.
[80] Silverstein, R.L., Leung, L.L., Harpel, P.C. and Nachman, R.L. (1984) Complex
formation of platelet thrombospondin with plasminogen. Modulation of
activation by tissue activator. J. Clin. Invest. 74, 1625–1633.
[81] Borza, D.B. and Morgan, W.T. (1997) Acceleration of plasminogen activation
by tissue plasminogen activator on surface-bound histidine-proline-rich
glycoprotein. J. Biol. Chem. 272, 5718–5726.
M.F.B.G. Gebbink et al. / FEBS Letters 583 (2009) 2691–2699
[82] Sheng, S., Truong, B., Fredrickson, D., Wu, R., Pardee, A.B. and Sager, R. (1998)
Tissue-type plasminogen activator is a target of the tumor suppressor gene
maspin. Proc. Natl. Acad. Sci. USA 95, 499–504.
[83] Lind, S.E. and Smith, C.J. (1993) Actin stimulates plasmin generation by tissue
and urokinase-type plasminogen activators. Arch. Biochem. Biophys. 307,
138–145.
[84] Tucker, H.M., Kihiko-Ehmann, M., Wright, S., Rydel, R.E. and Estus, S. (2000)
Tissue plasminogen activator requires plasminogen to modulate amyloidbeta neurotoxicity and deposition. J. Neurochem. 75, 2172–2177.
[85] Reijerkerk, A., Mosnier, L.O., Kranenburg, O., Bouma, B.N., Carmeliet, P.,
Drixler, T., Meijers, J.C., Voest, E.E. and Gebbink, M.F. (2003) Amyloid
endostatin induces endothelial cell detachment by stimulation of the
plasminogen activation system. Mol. Cancer Res. 1, 561–568.
[86] Bobbink, I.W., Tekelenburg, W.L., Sixma, J.J., de Boer, H.C., Banga, J.D. and de
Groot, P.G. (1997) Glycated proteins modulate tissue-plasminogen activatorcatalyzed plasminogen activation. Biochem. Biophys. Res. Commun. 240,
595–601.
[87] Gebbink, M.F., Claessen, D., Bouma, B., Dijkhuizen, L. and Wosten, H.A. (2005)
Amyloids—a functional coat for microorganisms. Nat. Rev. Microbiol. 3, 333–
341.
[88] Kingston, I.B., Castro, M.J. and Anderson, S. (1995) In vitro stimulation of
tissue-type plasminogen activator by Alzheimer amyloid beta-peptide
analogues. Nat. Med. 1, 138–142.
[89] Wnendt, S., Wetzels, I. and Gunzler, W.A. (1997) Amyloid beta peptides
stimulate tissue-type plasminogen activator but not recombinant
prourokinase. Thromb. Res. 85, 217–224.
[90] Ellis, V., Daniels, M., Misra, R. and Brown, D.R. (2002) Plasminogen activation
is stimulated by prion protein and regulated in a copper-dependent manner.
Biochemistry 41, 6891–6896.
[91] Radcliffe, R. and Heinze, T. (1981) Stimulation of tissue plasminogen
activator by denatured proteins and fibrin clots: a possible additional role
for plasminogen activator? Arch. Biochem. Biophys. 211, 750–761.
[92] Radcliffe, R. (1983) A critical role of lysine residues in the stimulation of
tissue plasminogen activator by denatured proteins and fibrin clots. Biochim.
Biophys. Acta 743, 422–430.
[93] Machovich, R. and Owen, W.G. (1997) Denatured proteins as cofactors for
plasminogen activation. Arch. Biochem. Biophys. 344, 343–349.
[94] Machovich, R., Komorowicz, E., Kolev, K. and Owen, W.G. (1999) Facilitation
of plasminogen activation by denatured prothrombin. Thromb. Res. 94, 389–
394.
[95] Haddeland, U., Bennick, A. and Brosstad, F. (1995) Stimulating effect on
tissue-type plasminogen activator—a new and sensitive indicator of
denatured fibrinogen. Thromb. Res. 77, 329–336.
[96] Haddeland, U., Sletten, K., Bennick, A., Nieuwenhuizen, W. and Brosstad, F.
(1996) Aggregated, conformationally changed fibrinogen exposes the
stimulating sites for t-PA-catalysed plasminogen activation. Thromb.
Haemost. 75, 326–331.
[97] Gebbink, M.F., Voest, E.E. and Reijerkerk, A. (2004) Do antiangiogenic protein
fragments have amyloid properties? Blood 104, 1601–1605.
[98] Thompson, W.D., Stirk, C.M., Melvin, W.T. and Smith, E.B. (1996) Plasmin,
fibrin degradation and angiogenesis. Nat. Med. 2, 493.
[99] Schielen, W.J., Voskuilen, M., Adams, P.J., Tesser, G.I. and Nieuwenhuizen, W.
(1990) Structural requirements of fibrinogen A alpha-(148–160) for the
enhancement of the rate of plasminogen activation by tPA. Blood Coagul.
Fibrinol. 1, 521–524.
[100] Syrovets, T. and Simmet, T. (2004) Novel aspects and new roles for the serine
protease plasmin. Cell Mol. Life Sci. 61, 873–885.
[101] Tsirka, S.E. (2002) Tissue plasminogen activator as a modulator of neuronal
survival and function. Biochem. Soc. Trans. 30, 222–225.
[102] Jacobsen, J.S., Comery, T.A., Martone, R.L., Elokdah, H., Crandall, D.L.,
Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., Zhou, H.,
Atchison, K., Wagner, E., Zaleska, M.M., Das, I., Arias, R.L., Bard, J., Riddell,
D., Gardell, S.J., bou-Gharbia, M., Robichaud, A., Magolda, R., Vlasuk, G.P.,
Bjornsson, T., Reinhart, P.H. and Pangalos, M.N. (2008) Enhanced clearance of
Abeta in brain by sustaining the plasmin proteolysis cascade. Proc. Natl.
Acad. Sci. USA 105, 8754–8759.
[103] Melchor, J.P., Pawlak, R. and Strickland, S. (2003) The tissue plasminogen
activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta)
degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23,
8867–8871.
[104] Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D.,
Walker, D., Scheff, S., McGillis, J.P., Rydel, R.E. and Estus, S. (2000) The
plasmin system is induced by and degrades amyloid-beta aggregates. J.
Neurosci. 20, 3937–3946.
[105] Tsirka, S.E., Gualandris, A., Amaral, D.G. and Strickland, S. (1995) Excitotoxininduced neuronal degeneration and seizure are mediated by tissue
plasminogen activator. Nature 377, 340–344.
[106] Busuttil, S.J., Ploplis, V.A., Castellino, F.J., Tang, L., Eaton, J.W. and Plow, E.F.
(2004) A central role for plasminogen in the inflammatory response to
biomaterials. J. Thromb. Haemost. 2, 1798–1805.
[107] Groenning, M., Norrman, M., Flink, J.M., van de, W.M., Bukrinsky, J.T.,
Schluckebier, G. and Frokjaer, S. (2007) Binding mode of thioflavin T in
insulin amyloid fibrils. J. Struct. Biol. 159, 483–497.
[108] Groenning, M., Olsen, L., van de, W.M., Flink, J.M., Frokjaer, S. and Jorgensen,
F.S. (2007) Study on the binding of thioflavin T to beta-sheet-rich and nonbeta-sheet cavities. J. Struct. Biol. 158, 358–369.
2699
[109] Bouma, B., Maas, C., Hazenberg, B.P., Lokhorst, H.M. and Gebbink, M.F. (2007)
Increased plasmin-alpha2-antiplasmin levels indicate activation of the
fibrinolytic system in systemic amyloidoses. J. Thromb. Haemost. 5, 1139–
1142.
[110] Vroman, L. and Adams, A.L. (1969) Identification of rapid changes at plasma–
solid interfaces. J. Biomed. Mater. Res. 3, 43–67.
[111] Soderquist, M. and Walton, A. (1980) Structural changes in proteins adsorbed
on polymer surfaces. J. Colloid Interf. Sci 75, 386–397.
[112] Ter-Minassian-Saraga, L. (1981) Protein denaturation on adsorption and
water activity at interfaces: an analysis and suggestion. J. Colloid Interf. Sci
80, 393–401.
[113] Chan, B.M.C. and Brash, J.L. (2009) Conformational change in fibrinogen
desorbed from glass surface. J. Colloid Interf. Sci 84, 263–265.
[114] Zhao, H., Tuominen, E.K. and Kinnunen, P.K. (2004) Formation of amyloid
fibers triggered by phosphatidylserine-containing membranes. Biochemistry
43, 10302–10307.
[115] Zhao, H., Jutila, A., Nurminen, T., Wickstrom, S.A., Keski-Oja, J. and Kinnunen,
P.K. (2005) Binding of endostatin to phosphatidylserine-containing membranes
and formation of amyloid-like fibers. Biochemistry 44, 2857–2863.
[116] Zhu, M., Souillac, P.O., Ionescu-Zanetti, C., Carter, S.A. and Fink, A.L. (2002)
Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277, 50914–50922.
[117] Samuel, M., Pixley, R.A., Villanueva, M.A., Colman, R.W. and Villanueva, G.B.
(1992) Human factor XII (Hageman factor) autoactivation by dextran sulfate.
Circular dichroism, fluorescence, and ultraviolet difference spectroscopic
studies. J. Biol. Chem. 267, 19691–19697.
[118] Vogler, E.A. and Siedlecki, C.A. (2009) Contact activation of blood–plasma
coagulation. Biomaterials 30, 1857–1869.
[119] Manning, M.C., Patel, K. and Borchardt, R.T. (1989) Stability of protein
pharmaceuticals. Pharm. Res. 6, 903–918.
[120] Zhuo, R. and Vogler, E.A. (2006) Practical application of a chromogenic FXIIa
assay. Biomaterials 27, 4840–4845.
[121] Maas, C., Schiks, B., Strangi, R.D., Hackeng, T.M., Bouma, B.N., Gebbink, M.F.
and Bouma, B. (2008) Identification of fibronectin type I domains as amyloidbinding modules on tissue-type plasminogen activator and three homologs.
Amyloid 15, 166–180.
[122] Verheijen, J.H., Caspers, M.P., Chang, G.T., de Munk, G.A., Pouwels, P.H. and
Enger-Valk, B.E. (1986) Involvement of finger domain and kringle 2 domain
of tissue-type plasminogen activator in fibrin binding and stimulation of
activity by fibrin. EMBO J. 5, 3525–3530.
[123] Matsuka, Y.V., Medved, L.V., Brew, S.A. and Ingham, K.C. (1994) The NH2terminal fibrin-binding site of fibronectin is formed by interacting fourth and
fifth finger domains. Studies with recombinant finger fragments expressed in
Escherichia coli. J. Biol. Chem. 269, 9539–9546.
[124] Nieuwenhuizen, W. (2001) Fibrin-mediated plasminogen activation. Ann.
N.Y. Acad. Sci. 936, 237–246.
[125] Doolittle, R.F. (2008) Searching for differences between fibrinogen and fibrin
that affect the initiation of fibrinolysis. Cardiovasc. Hematol. Agents Med.
Chem. 6, 181–189.
[126] Hazenberg, B.P., van Rijswijk, M.H., Piers, D.A., Lub-de Hooge, M.N., Vellenga,
E., Haagsma, E.B., Hawkins, P.N. and Jager, P.L. (2006) Diagnostic performance
of 123I-labeled serum amyloid P component scintigraphy in patients with
amyloidosis. Am. J. Med. 119. 355.e15–355.e24.
[127] Hudry-Clergeon, G., Freyssinet, J.M., Torbet, J. and Marx, J. (1983) Orientation
of fibrin in strong magnetic fields. Ann. N.Y. Acad. Sci 408, 380–387.
[128] Sanchez, J., Elgue, G., Larsson, R., Nilsson, B. and Olsson, P. (2008) Surfaceadsorbed fibrinogen and fibrin may activate the contact activation system.
Thromb. Res. 122, 257–263.
[129] Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A.,
Capila, I., Lansing, J.C., Guglieri, S., Fraser, B., Al-Hakim, A., Gunay, N.S., Zhang,
Z., Robinson, L., Buhse, L., Nasr, M., Woodcock, J., Langer, R., Venkataraman,
G., Linhardt, R.J., Casu, B., Torri, G. and Sasisekharan, R. (2008) Oversulfated
chondroitin sulfate is a contaminant in heparin associated with adverse
clinical events. Nat. Biotechnol. 26, 669–675.
[130] Kishimoto, T.K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S.,
Pelzer, K., Lansing, J.C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., AlHakim, A., Bailey, G.S., Fraser, B., Roy, S., Rogers-Cotrone, T., Buhse, L., Whary,
M., Fox, J., Nasr, M., Dal Pan, G.J., Shriver, Z., Langer, R.S., Venkataraman, G.,
Austen, K.F., Woodcock, J. and Sasisekharan, R. (2008) Contaminated heparin
associated with adverse clinical events and activation of the contact system.
N. Engl. J. Med. 358, 2457–2467.
[131] Yan, S.D., Stern, D., Kane, M.D., Kuo, Y.M., Lampert, H.C. and Roher, A.E. (1998)
RAGE-Abeta interactions in the pathophysiology of Alzheimer’s disease.
Restor. Neurol. Neurosci. 12, 167–173.
[132] Yan, S.D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C.,
Schmidt, A.M., Stern, D. and Kindy, M. (2000) Receptor-dependent cell stress
and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643–651.
[133] El Khoury, J.B., Moore, K.J., Means, T.K., Leung, J., Terada, K., Toft, M., Freeman,
M.W. and Luster, A.D. (2003) CD36 mediates the innate host response to
beta-amyloid. J. Exp. Med. 197, 1657–1666.
[134] Deane, R., Sagare, A. and Zlokovic, B.V. (2008) The role of the cell surface LRP
and soluble LRP in blood–brain barrier Abeta clearance in Alzheimer’s
disease. Curr. Pharm. Des. 14, 1601–1605.
[135] Bouma, B., Kroon-Batenburg, L.M., Wu, Y.P., Brunjes, B., Posthuma, G.,
Kranenburg, O., de Groot, P.G., Voest, E.E. and Gebbink, M.F. (2003)
Glycation induces formation of amyloid cross-beta structure in albumin. J.
Biol. Chem. 278, 41810–41819.